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Abstract
Objective: One of the factors associated with low rates of compliance in the treatment for 
alcoholism seems to be the intensity of craving for alcohol. This study aimed to evaluate the 
associations between alcohol craving and biopsychosocial addiction model-related variables and to 
verify whether these variables could predict treatment retention. Methods: The sample consisted 
of 257 male alcoholics who were enrolled in two different pharmacological trials conducted at the 
Universidade de São Paulo in Brazil. Based on four factors measured at baseline – biological (age, 
UDFHDQGIDPLO\DOFRKROLVPSV\FKLDWULFGHSUHVVLRQV\PSWRPVVRFLDOÀQDQFLDODQGPDULWDO
status), and addiction (craving intensity, severity of alcohol dependence, smoking status, drinking 
history, preferential beverage, daily intake of alcohol before treatment) – direct logistic regression 
ZDV SHUIRUPHG WR DQDO\]H WKHVH IDFWRUV· LQÁXHQFH RQ WUHDWPHQW UHWHQWLRQ DIWHU FRQWUROOLQJ
for medication groups and AA attendance. Results: Increasing age, participation in Alcoholics 
Anonymous groups, and beer preference among drinkers were independently associated with 
higher treatment retention. Conversely, higher scores for depression increased dropout rates. 
Conclusion: Health services should identify the treatment practices and therapists that improve 
retention. Information about patients’ characteristics linked to dropouts should be studied 
to render treatment programs more responsive and attractive, combining pharmacological agents 
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Preditores psicossociais e clínicos de retenção ao tratamento para alcoolismo
Resumo
Objetivo: Um dos fatores associados com baixas taxas de adesão ao tratamento para alcoolismo 
SDUHFHVHUDLQWHQVLGDGHGDÀVVXUDSHORiOFRRO(VWHHVWXGRREMHWLYDDYDOLDUDDVVRFLDomRHQWUHD
ÀVVXUDSHORiOFRROHYDULiYHLVUHODFLRQDGDVDRPRGHORELRSVLFRVVRFLDOGHGHSHQGrQFLDEHPFRPR
YHULÀFDUVHHVWDVYDULiYHLVSUHYrHPUHWHQomRDRWUDWDPHQWRMétodo: A amostra foi composta 
SRUKRPHQVGHSHQGHQWHVGHiOFRROTXHSDUWLFLSDUDPGHGRLVGLIHUHQWHVHVWXGRVFOtQLFRVTXH
foram desenvolvidos na Universidade de São Paulo, Brasil. Baseado em quatro fatores medidos 
QRLQtFLRGRWUDWDPHQWR²ELROyJLFRLGDGHUDoDHDOFRROLVPRIDPLOLDUSVLTXLiWULFRVLQWRPDV
GHSUHVVLYRVVRFLDOFRQGLomRHFRQ{PLFDHVWDWXVPDULWDOHUHODFLRQDGRjGHSHQGrQFLDLQWHQVLGDGH
GDÀVVXUDJUDYLGDGHGDGHSHQGrQFLDGRiOFRROVWDWXVGHVHUIXPDQWHWHPSRGHFRQVXPRUHJXODU
HSUREOHPiWLFRGHEHELGDVDOFRyOLFDVEHELGDSUHIHUHQFLDOTXDQWLGDGHGHHWDQROFRQVXPLGRDRGLD
²XPPRGHORGHUHJUHVVmRORJtVWLFDGLUHWDIRLGHVHQYROYLGRSDUDDQDOLVDURHIHLWRGHVWDVYDULiYHLV
VREUHDUHWHQomRDRWUDWDPHQWRFRQWURODQGRSDUDDLQÁXrQFLDGDVPHGLFDo}HVXWLOL]DGDVHGD
SDUWLFLSDomRHPJUXSRVGHDOFRyOLFRVDQ{QLPRVResultados0DLVLGDGHSDUWLFLSDomRHPJUXSRV
GHDOFRyOLFRVDQ{QLPRVHSUHIHUrQFLDSRUFHUYHMDIRUDPIDWRUHVLQGHSHQGHQWHPHQWHDVVRFLDGRV
DPDLRUUHWHQomRDRWUDWDPHQWR0DLRUHVFRUHHPGHSUHVVmRDXPHQWRXDFKDQFHGHDEDQGRQR
Conclusão6HUYLoRVGHVD~GHGHYHPLGHQWLÀFDUSUiWLFDVHSURÀVVLRQDLVTXHSURSRUFLRQHPPHOKRUD
QDVWD[DVGHUHWHQomR,QIRUPDomRVREUHDVFDUDFWHUtVWLFDVGRVSDFLHQWHVUHODFLRQDGDVDRDEDQGRQR
GHYHPVHUXVDGDVSDUDWRUQDUSURJUDPDVGHWUDWDPHQWRPDLVHÀFLHQWHVHDWUDHQWHVFRPELQDQGR
DJHQWHVIDUPDFROyJLFRVFRPPDLVLQWHQVLYDVHGLYHUVLÀFDGDVLQWHUYHQo}HVSVLFRVVRFLDLV
DESCRITORES:
(VWXGRVFOtQLFRV
Fissura; 
*UXSRVGH$OFRyOLFRV
$Q{QLPRV
,QWHUYHQo}HV
Psicossociais.
Introduction
The rates of compliance with treatment for alcoholism are as 
low as those for other chronic medical disorders. Poor treat-
ment adherence represents a reduction in quality of life and 
a loss of life years for many patients. Over the last 30 years, 
UHVHDUFKHUVKDYHLGHQWLÀHGVHYHUDOFOLHQWFHQWHUHGIDFWRUV
associated with early discontinuation of substance abuse 
treatment, such as youth, single social status, high severity 
of substance use, family alcoholism, and depression. With 
regard to treatment-centered factors, negative therapeutic 
alliance, low clinician experience, and inadequate engage-
ment of family members in treatment have been associated 
with high rates of treatment abandonment and relapses 
during follow-up.1,2
Many of these client-centered factors have been positively 
correlated with craving intensity. Despite the subjective na-
ture of and diverse theories surrounding this theme, craving 
has been positively correlated with younger age,3 alcohol 
dependence severity,4 family alcoholism,5 and negative 
moods or emotional status.6 Other factors, such as stress 
exposure,7 preferred beverage,8 history of recurrent detoxi-
ÀFDWLRQV9 and smoking status,10 have also been associated 
with craving intensity. Hence, craving has been considered a 
better predictor of relapse than other variables, such as 
psychosocial functioning, treatment duration, and alcohol-
ism severity levels.5 
Alcohol craving is thought to appear either from the desire 
to have alcohol's positive effects (i.e., positive reinforce-
ment) or from the desire to circumvent the negative effects 
of withdrawal symptoms (i.e., negative reinforcement), but 
further models have proposed other important dimensions 
of craving, such as the desire and intention to consume 
alcohol, lack of control over alcohol use, preoccupation with 
drinking-related thoughts and/or behavior among others. 
Therefore, certain aspects of craving can better characterize 
the experience of some alcoholics than that of others, which 
FDQUHQGHUWKHHYDOXDWLRQRIFUDYLQJH[WUHPHO\GLIÀFXOW11 
In addition, the quality and intensity of craving can vary in 
accordance with personal characteristics and environmental 
circumstances.
Treatments for alcoholism have been developed to reduce 
craving and, consequently, alcohol consumption. Currently, 
four agents are approved by the Food and Drug Administration 
WRWUHDWDOFRKROLVPGLVXOÀUDPDFDPSURVDWHRUDOQDOWUH[-
one, and once-monthly, injectable, extended-release nal-
WUH[RQH1RWZLWKVWDQGLQJVRPHLQFRQVLVWHQWÀQGLQJVWKHVH
agents have demonstrated some ability to reduce craving and 
LQFUHDVHDEVWLQHQFHWLPH([FHSWIRUGLVXOÀUDPZKLFKKDVDQ
aversive mechanism of action, effective pharmacotherapies 
for alcohol dependence are thought to work by blocking the 
rewards of alcohol or by stabilizing the systems dysregulated 
by chronic alcohol intake, making craving less intense.12 
In addition, off-label medications, such as topiramate 
and ondansetron, have also been shown to reduce craving and 
increase abstinence time.13,14 The ability to reduce craving 
should then be associated with the likeliness to increase 
treatment retention, at least to some extent.
A range of studies have demonstrated that longer dura-
tions of treatment and treatment completion are associated 
with better outcomes in alcoholism-treatment programs.15 
We are aware that treatment retention is not an outcome 
measurement on its own; however, the capacity to retain 
patients in active participation is a sensible measurement 
DVVRFLDWHGZLWK WKH TXDOLW\ DQG HIÀFDF\ RI KHDOWK FDUH
415Predictors of treatment retention
Additionally, according to the UK’s National Treatment Agency 
for Substance Misuse, retention in drug treatment is the best 
available measurement of treatment effectiveness.16
In this present study, we evaluated the associations 
between alcohol craving (measured using the Obsessive 
Compulsive Drinking Scale – OCDS) and diverse previously 
tested variables in the biopsychosocial addiction model. 
6SHFLÀFDOO\ ZH LQYHVWLJDWHG WKH UHODWLRQVKLS RI DOFRKRO
craving with the following factors: (1) biological: age, race, 
and family alcoholism; (2) addiction: severity of alcohol 
dependence, smoking status, drinking history, preferred 
beverage, and daily intake of alcohol before treatment; (3) 
SV\FKLDWULFGHSUHVVLRQV\PSWRPVDQGVRFLDOÀQDQFLDO
and marital status. Additionally, we evaluated whether crav-
ing intensity and any of the above variables could predict 
treatment retention, when different pharmacotherapies and 
participation in Alcoholics Anonymous groups were also taken 
into account. In addition, given the role of craving intensity 
on attrition rates, we hypothesized that craving (measured 
by the OCDS) would be a strong predictive factor of treat-
ment, even after controlling for other variables potentially 
correlated with this variable. 
Methods
Databases of two randomized, double-blind, placebo-con-
trolled clinical trials were combined for this joint analysis. 
7KHVHWULDOVZHUHSHUIRUPHGWRGHWHFWWKHHIÀFDF\RIDFWLYH
medications in reducing drinking, promoting abstinence and 
decreasing cravings in alcohol-dependent outpatients. The 
pharmacological treatments lasted 12 weeks. Each study was 
approved by the Ethics Committee of the Clinical Hospital 
RIWKH8QLYHUVLGDGHGH6mR3DXORLQ%UD]LO0RUHVSHFLÀFDOO\
we combined the databases from the following double-blind 
studies, which evaluated craving intensity by applying the 
Obsessive Compulsive Drinking Scale (OCDS): (A) a trial, 
performed between 2004 and 2007, comparing topiramate 
(up to 300 mg/day), naltrexone (50 mg/day) and placebo;14 
and (B) a study, conducted between 2008 and 2010, com-
paring ondansetron (16 mg/day) with placebo. These trials 
were coordinated by the same doctor and were developed 
in the same clinical setting, following the same behavioral 
approaches and double-blind principle.
Participants
Male patients, 18-60 years of age, with an International 
&ODVVLÀFDWLRQRI'LVHDVHV,&':RUOG+HDOWK2UJDQL]DWLRQ
1992) diagnosis of alcohol dependence and who were enrolled 
as outpatients in the Assistance Sector of the Interdisciplinary 
Group of Studies on Alcohol and Drugs at the Universidade de 
São Paulo (GREA) were assessed for each trial. This service 
(GREA) is dedicated to the treatment of men who abuse or 
are dependent on alcohol and/or any other type of drug.
The exclusion criteria were (a) younger than 18 years of 
age or older than 60 years of age; (b) a current diagnosis 
of dependence or abuse of other substances except for 
nicotine; (c) patients with serious coexisting clinical diseases 
(e.g., inadequately controlled diabetes, cardiac failure, alco-
holic cirrhosis); (d) previous treatment with any medication 
to treat alcoholism within six months of randomization; (e) 
FRQFRPLWDQWSV\FKLDWULFGLVRUGHUVWKDWPLJKWUHTXLUHVSHFLÀF
drug treatment; (f) inability to provide full informed consent; 
and (g) a clinical history of mental retardation, as it reduced 
the accuracy of the information given.
For each study, all of the subjects provided written in-
formed consent. They were informed about the objectives 
of each study, the nature of the treatment offered, and the 
SURÀOHVRIWKHPHGLFDWLRQVWHVWHGDQGWKDWWKHPHGLFDWLRQV
they would receive would be chosen at random. All of the 
SDWLHQWVZHUHDVVXUHGDERXWWKHFRQÀGHQWLDOLW\RIWKHGDWD
and were informed that they were free to withdraw their 
consent and discontinue participation in the studies at any 
time without prejudice regarding their continued medical 
care. All of the participants were encouraged to participate in 
Alcoholics Anonymous groups (AA), but this participation was 
not an obligatory condition of participating in these trials.
Measurements
,Q WKH ÀUVW LQWHUYLHZ IRU HDFK WULDO DIWHU D IXOO KLVWRU\ 
DQGFOLQLFDOH[DPLQDWLRQSDWLHQWVZKRIXOÀOOHGWKH LQFOX-
sion criteria were evaluated. Socio-demographic data and 
lifetime drinking history, such as family antecedents of 
alcohol problems, daily intake of alcohol in grams, drinking 
onset age, age at onset of regular alcohol consumption, and 
problem drinking onset age, were obtained in a standardized 
semi-structured interview commonly used in the therapeutic 
setting of the Interdisciplinary Group of Studies on Alcohol 
and Drugs of the Clinical Hospital of the Universidade de 
São Paulo in Brazil.
$OO RI WKH SDWLHQWVZHUH HYDOXDWHG DW WKH ÀUVW LQWHU-
view with the Short Alcohol Dependence Data (SADD),17 
the Hamilton Depression Rating Scale (HDRS),18 and the 
Obsessive-Compulsive Drinking Scale (OCDS).19 Blood 
was taken for a routine full blood count and for liver func-
tion tests.
A weighting scale was adopted to evaluate family alco-
KROLVP7KHIROORZLQJJUDGHZDVXVHGSRLQWVIRUÀUVW
degree relatives and 0.25 points for second-degree relatives. 
A rigorous analysis of the incidence of alcohol dependence 
LQÀUVWDQGVHFRQGGHJUHHUHODWLYHVZDVSHUIRUPHGLQOLQH
with another study.20
Additionally, the participants were questioned about their 
current average daily consumption of beer, spirits, and wine, 
with regard to the duration of use and the time of drinking 
(morning, afternoon, or night). Beer preference drinkers 
ZHUHWKHQGHÀQHGDVWKRVHZKRGUDQNPRUHEHHUWKDQVSLU-
its or wine and accordingly for spirits and wine preference 
GULQNHUV )RU DPRUH SUHFLVH FODVVLÀFDWLRQZH GHÀQHG D
particular type of alcoholic beverage as “predominant” if 
the consumption of that type of beverage accounted for 
two-thirds or more of the total of ethanol consumed during 
WKHODVW\HDU7KLVFODVVLÀFDWLRQZDVXVHGLQDSUHYLRXVVWXG\4
At each appointment, the participants were also asked 
about their participation in AA, and those subjected that 
attended AA at least once a week were considered to be 
adherent to this self-help group.
Procedure
$OO RI WKH SDWLHQWV XQGHUZHQW D WZRZHHN GHWR[LÀFDWLRQ
period prior to initiating active medication or placebo. This 
GHWR[LÀFDWLRQSHULRGZDVFRQGXFWHGRQDQRXWSDWLHQWEDVLV
and the patients were given medications, such as lorazepam 
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up to 6 mg/day and vitamin B1 300 mg/day, in cases of the 
manifesting of withdrawal symptoms. Laboratory exams, 
including liver function, were collected during this period. 
The patients manifested minimal to moderate withdrawal 
symptoms, which allowed them to be treated on an outpa-
tient basis.
At each appointment, all of the patients received 
standardized and manual brief cognitive behavioral in-
terventions. The overall goal of these interventions was 
to increase the subjects’ ability to cope with high-risk 
situations that could precipitate relapses. The following 
topics were standardized and applied to each patient 
during treatment: management of negative mood, asser-
tiveness, drink refusal skills, enhancement of social support 
networks and relapse prevention.
For each trial, all capsules were adequately manufactured 
to have identical appearances, thus avoiding any double-
blind violation.
Treatment retention was one of the outcome measure-
ments used in this joint study. We considered three reasons 
for dropping out of the trials: (a) “refuses to continue” 
WKHSDWLHQWDIÀUPHGWKDWKHZDQWHGWRVWRSWKDWW\SHRI
treatment and to try others, e.g., psychotherapy only); 
(b) “protocol violation” (the patient used other pharmaco-
logic drugs during the studies); and (c) “lost to follow-up” 
(the patient gave up following the studies and did not mani-
fest any desire to be treated differently). The patients who 
remained in treatment for all 12 weeks were considered 
completers. The patients who did not attend follow-ups were 
considered discontinuers.
Data analysis
The Kolmogorov-Smirnov test was used to evaluate whether 
the variables were normally distributed. The following 
variables had to be square-root transformed: OCDS and 
HDRS mean levels and the quantity of ethanol per day. 
Direct logistic regression analysis (Wald’s method) was 
performed to investigate associations between treatment 
outcome (completers versus discontinuers) and the fol-
lowing predictive variables measured at baseline: age, 
race, marital status, depressive symptoms (measured by 
+'56 ÀQDQFLDO FRQGLWLRQPDULWDO VWDWXV WLPH SHULRG
since the regular drinking onset age, time period since 
the problem drinking onset age, preferred beverage, daily 
intake of alcohol before treatment, medication groups, AA 
attendance, severity of alcohol dependence (measured by 
SADD), and craving for alcohol (measured by OCDS). Given 
that all of the predictors were entered into the equation 
simultaneously (as long as tolerance was not violated), a 
predictor that was highly correlated with the outcome by 
itself might have shown little predictive capability in the 
presence of other highly correlated predictors. Therefore, 
we also computed the correlation matrix of the variables 
LQFOXGHGLQORJLVWLFUHJUHVVLRQDQDO\VLV3HDUVRQ·VUŔDQG
SRLQWELVHULDOFRUUHODWLRQFRHIÀFLHQWVZHUHXVHGWRLQGL-
cate the relationships between two continuous variables, 
two categorical variables, and between one continuous 
variable and one categorical variable, respectively. The 
data were analyzed using SPSS Statistics for Windows, 
version 18.0.
Results
Our sample was composed of 257 men, aged between 23 and 
60 years of age (mean 43.76; SD 8.92). Approximately 56% 
were married, 56% were white, 53% had not reached high 
school, and 65% were Christian. One hundred seventy-six 
(69%) reported being smokers. Out of 257 participants, 136 
(52.92%) completed the studies. The baseline characteristics 
of this study population are displayed in Table 1.
As shown in Table 2, direct logistic regression analysis 
(Wald’s method) was performed on group status (completers 
and discontinuers) as an outcome and on the following predic-
tors: medication groups and participation in AA as treatment-
related variables; and OCDS, SADD, and HDRS mean scores, 
age at the beginning of current treatment, time since the 
beginning of regular alcohol use, time since the problem 
drinking onset age, family alcoholism, preferred beverage, 
tobacco consumption, quantity of ethanol per day (before 
the current treatment), history of previous treatment for 
DOFRKROLVPUDFHPDULWDOVWDWXVDQGÀQDQFLDOVLWXDWLRQZHUH
treated as variables possibly related to craving intensity. We 
chose this method despite the fact that some predictors could 
be strongly associated with other ones and, as a result, some 
of them could mask the effect of others. In this analysis, “age 
at the beginning of the current treatment”, “participation 
in AA”, “HDRS mean levels”, and “beer preference drinkers” 
predicted treatment outcome. The model was statistically 
UHOLDEOHŲ2 = 44.48, 21 df, p < 0.01). The variance in group 
membership accounted for was low, with Nagelkerke R2 = 
0.21. The overall prediction success was 65.8%. We checked 
WKHÀWRIRXUPRGHOXVLQJ+RVPHUDQG/HPHVKRZ·VWHVWŲ2 
= 8.15, 8 df, p = 0.42).
We also performed another direct logistic regression 
DQDO\VLVLQYROYLQJRQO\WKHYDULDEOHVWKDWZHUHVLJQLÀFDQWO\
associated with treatment retention in the previous analysis. 
As shown in Table 3, ‘age at the beginning of the current 
treatment’, ‘participation in AA’, and ‘HDRS mean levels’ 
UHPDLQHGVLJQLÀFDQWO\DVVRFLDWHGZLWKWUHDWPHQWUHWHQWLRQ
Conversely, ‘beer preference’ did not predict retention in 
this latter analysis. This model was statistically reliable, 
Ų2 = 24.55, 5 df, p < 0.01). The variance in group member-
ship accounted for was marginal, with Nagelkerke R2 = 0.12. 
7KHRYHUDOOSUHGLFWLRQVXFFHVVZDV7KHPRGHOÀWZDV
FKHFNHGXVLQJ+RVPHUDQG/HPHVKRZ·VWHVWŲ2 = 8.89, 8 df, 
p = 0.35).
Table 4 shows correlation analyses involving variables 
measured at baseline. Although correlations inferior to 0.50 
VKRXOGEHFRQVLGHUHGQRQVLJQLÀFDQWZHGHFLGHGWRVKRZ
all correlations with p-values of less than 0.05. As shown 
in Table 4, OCDS was negatively associated with age at the 
beginning of each trial and with the status of being married 
but was positively correlated with family alcoholism, severity 
of alcohol dependence, preferential consumption of spirits, 
and quantity of ethanol consumed before each trial.
Discussion
This study supports previous evidence that alcohol craving 
is positively correlated with family alcoholism, dependence 
severity, and quantity of ethanol consumed per day but 
negatively associated with the patient’s age. In addition, 
alcohol craving was positively correlated with a preference 
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Table 1 Baseline characteristics
Characteristic Patients
(n = 257)
Age, mean (SD) 43.76 (8.92)
Race, n (%)
 White 144 (56.03)
 Black 33 (12.84)
 Mixed race 80 (31.13)
Marital status, n (%)
 Married 144 (56.03)
 Single 41 (15.95)
 Separated/Widower 72 (28.02)
Quantity of ethanol per day (in grams),a mean (SD) 297.77 (178.41)
History of having received previous treatment for alcoholism, n (%) 139 (54.09)
Monthly income (in R$, the Brazilian currency), mean (SD) 1,085.72 (1002.35)
Preferred beverage, n (%)
 Spirits 183 (71.20)
 Beer 71 (27.63)
 Wine 3 (1.17)
Medication groups, n (%)
 Placebo 106 (41.24) 
 Topiramate 52 (20.23)
 Naltrexone 49 (19.07)
 Ondansetron 50 (19.46)
Smoking, n (%) 177 (68.87)
OCDS, mean (SD) 47.99 (12.18)
SADD, mean (SD) 27.73 (8.28)
HDRS, mean (SD) 9.90 (6.38)
Time since the regular drinking onset age (in years) 17.98 (9.63)
Time since the problem drinking onset age (in years) 11.19 (9.12)
Plasma GGT, U/L; (reference range 8-61), mean (SD) 144.56 (254.71)
Plasma ALT, U/L; (reference range < 41), mean (SD) 38.04 (29.16)
Plasma AST, U/L; (reference range < 37), mean (SD) 42.04 (35.27)
Plasma MCV, f/L; (reference range 80-100), mean (SD) 94.77 (7.22)
a Indicates alcohol usage during the last three months preceding each study.
OCDS: Obsessive Compulsive Drinking Scale; SADD: Short Alcohol Dependence Data; HDRS: Hamilton Depression Rating Scale; GGT: gamma-glutamyl transferase; 
ALT: alanine aminotransferase; AST: aspartate aminotransferase; MCV: mean cellular volume.
for spirits. Increasing age, lower scores for depression, beer 
preference, and AA attendance predicted higher treatment 
retention. Contrary to our initial hypothesis, the variable 
‘craving’ (measured by the OCDS at baseline) was not a strong 
predictive factor of treatment retention.
Other studies on patients with impulsive behaviors have 
already shown a decrease in impulsive and compulsive symp-
toms with increasing age, and this relationship also seems to 
be true among alcoholics.3 In fact, a progressive reduction of 
daily alcohol intake,21 a decrease in mesolimbic neurotrans-
mission, and changes in the hypothalamic-pituitary-adrenal 
(HPA)22 and hypothalamic-pituitary-thyroid23 axes have been 
hypothesized to be possible causal mechanisms for craving 
reduction with increasing age. Parallel to these studies, there 
has been some evidence that older age can predict better 
compliance with alcoholism treatment.24
In our study, higher scores for depression predicted 
HDUO\ GLVFRQWLQXDWLRQ RI WUHDWPHQW 'HVSLWH WKLV ÀQGLQJ
research has shown mixed results regarding the relationship 
between depression symptoms and treatment retention.25 
Nevertheless, it is important to note that depression was 
positively correlated with longer drinking careers and more 
frequent histories of being previously treated for alcohol-
ism. In fact, negative experiences with previous alcoholism 
treatment could have a negative impact on the future cli-
ent's readiness to accept help for alcohol problems. The 
awareness that a previous experience was negative can 
powerfully change behavior and clinical outcomes.26 It is 
also important to stress that no participant was severely 
GHSUHVVHGRUUHTXLUHGVSHFLÀFWUHDWPHQWIRUGHSUHVVLRQLQ
the present study, given that depression was an exclusion 
criterion for both trials.
Beer preference drinkers showed higher treatment reten-
WLRQWKDQVSLULWVDQGZLQHSUHIHUHQFHGULQNHUV7KLVÀQGLQJ
was already discussed in a previous study published by our 
group.47KLVÀQGLQJZDVGLIIHUHQWIURPRWKHUVWXGLHVWKDWUH-
ported higher craving among beer preference drinkers, prob-
ably due to the greater volume intake of beer compared to 
other beverages.27+RZHYHUWKHLQÁXHQFHRIGLIIHUHQWW\SHV 
of beverages on craving and adherence to treatment can 
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Table 2 Effects of clinical and psychosocial variables at baseline on treatment retention (direct logistic regression)
Variables SE Wald df p OR CI (95%)
Age 0.02 4.96 1 0.02* 1.05 1.01-1.09
Race
 White (reference) 0.45 0.11 1 0.74 1.16 0.48-2.81
 Black 0.33 2.55 1 0.11 0.59 0.31-1.13
 Mixed races
Marital status
 Married (reference)
 Single 0.42 1.01 1 0.31 1.52 0.67-3.45
 Separated/Widowed 0.34 0.89 1 0.34 0.73 0.37-1.41
Quantity of ethanol per day (in grams) < 0.01 0.14 1 0.71 > 0.99 0.99-1.01
Previous treatments for alcoholism 0.29 0.13 1 0.72 1.11 0.63-1.95
Monthly income < 0.01 3.62 1 0.06 > 0.99 0.99-1.01
Preferred beverage
 Spirits (reference)
 Beer 0.33 4.07 1 0.04* 1.95 1.02-3.75
 Wine 1.32 0.72 1 0.39 3.07 0.23-41.04
Medication groups
Placebo (reference)
Ondansetron 0.40 2.85 1 0.09 1.96 0.90-4.30
Naltrexone 0.40 2.20 1 0.14 1.82 0.82-3.99
Topiramate 0.40 1.55 1 0.21 1.65 0.75-3.65
Smoking 0.32 0.30 1 0.58 1.19 0.64-2.23
OCDS 0.02 < 0.01 1 0.95 0.99 0.97-1.03
SADD 0.02 < 0.01 1 0.94 1.01 0.95-1.05
HDRS 0.02 5.56 1 0.02* 0.95 0.90-0.99
Years since the regular drinking onset age 0.03 1.27 1 0.26 1.03 0.98-1.08
Years since the problem drinking onset age 0.02 2.44 1 0.12 0.96 0.92-1.01
AA Attendance 0.48 5.70 1 0.02* 3.12 1.23-7.97
* p < .05; ** p < .01;
OCDS: Obsessive Compulsive Drinking Scale; SADD: Short Alcohol Dependence Data; HDRS: Hamilton Depression Rating Sacle; AA: Alcoholics Anonymous.
Table 3 'LUHFWORJLVWLFUHJUHVVLRQPRGHOLQFOXGLQJRQO\WKHYDULDEOHVWKDWZHUHVLJQLÀFDQWO\DVVRFLDWHGZLWKWUHDWPHQW
retention in Table 2
Variables SE Wald df p OR CI (95%)
Age 0.02 9.16 1 < 0.01** 1.05 1.02-1.08
Preferred beverage
 Spirits (reference)
 Beer 0.30 3.52 1 0.06 1.75 0.98-3.15
 Wine 1.26 0.17 1 0.68 1.68 0.14-19.89
HDRS 0.02 4.34 1 0.03* 0.96 0.92-0.99
AA Attendance 0.45 5.03 1 0.02* 2.73 1.13-6.55
* p < 0.05; ** p < 0.01;
HDRS, Hamilton Depression Rating Sacle; AA: Alcoholics Anonymous.
be a byproduct of several confounding variables, such 
as cultural and socioeconomic factors. Although greater 
volume intake among beer drinkers is related to craving 
LQWHQVLW\PDLQO\GXHWRLWVLQÁXHQFHRQYROXPHUHJXODWLQJ
peptides, spirits drinkers can consume greater quantities 
of ethanol per day than beer drinkers. Alcohol craving is 
also associated with the daily amount of ethanol consumed 
and with the severity of alcohol dependence.4 In our study, 
the correlations between these two variables (alcoholism 
severity and quantity of ethanol) in spirits drinkers were 
SRVLWLYHDQGVLJQLÀFDQW
3DUWLFLSDWLRQLQ$$ZDVVLJQLÀFDQWO\FRUUHODWHGZLWKUH-
tention in treatment. To date, there has been no conclusive 
VFLHQWLÀFHYLGHQFHWKDWSDUWLFLSDWLRQLQ$$NHHSVSDWLHQWV
in treatment longer.28,QJHQHUDORQHRIWKHGLIÀFXOWLHVLQ
evaluating the effectiveness of participation in AA is the 
self-selection bias of those who participate.29 Because 
individuals self-select themselves for participation in AA, 
otherwise known as selection bias, it is not clear whether 
there are personality or motivational factors related to the 
decision to join this self-help group. Some authors have 
reported that alcoholics who attend AA are typically more 
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Table 4 Correlation matrix of the variables included in the multivariate analyses (Pearson’s r, Phi, point-biserial)
Variables (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14)
(1) OCDS -
(2) Age at the beginning of each trial -0.22** -
(3) Race (white) ns ns -
(4) Family alcoholism 0.20** ns ns -
(5) SADD 0.70** -0.22** ns 0.23** -
(6) Smoking ns ns 0.13* ns ns -
(7) Time since the regular drinking  
onset age (in years)
ns 0.60** ns 0.14* ns ns -
(8) Time since the problem drinking  
onset age (in years)
ns 0.40** ns ns ns ns 0.75** -
(9) Preferred beverage (spirits) 0.16** ns ns ns 0.23** ns ns ns -
(10) Quantity of ethanol per day 0.37** -0.19** ns 0.15* 0.35** ns -0.18** -0.16* 0.15* -
(11) HDRS ns ns ns ns ns ns 0.18** 0.14* ns ns -
(12) Marital status (married) -0.22** 0.19** ns ns -0.26** ns 0.14* ns ns -0.15* ns -
(13) Monthly income ns ns ns ns -0.16** ns ns ns -0.14* ns -0.15* ns -
(14) Previous treatments for alcoholism ns ns ns ns ns ns ns ns ns ns 0.16** ns ns -
SSQVQRWVLJQLÀFDQW
OCDS: Obsessive Compulsive Drinking Scale; SADD: Short Alcohol Dependence Data; HDRS: Hamilton Depression Rating Scale.
VRFLDEOH DQG DIÀOLDWLYHPRUH JXLOW\ RYHU SDVW EHKDYLRU
physically healthier, and more socially stable.30 Conversely, 
RWKHUDXWKRUVKDYHDIÀUPHGWKDWDWWHQGDQFHDW$$LVPRUH
common among racial and ethnic minority groups, those 
with lower incomes, and those with unstable employment.31 
Although these generalizations can be problematic and 
doubtful, some characteristics attributed to AA participants 
have a certain level of acceptability, given the inherent 
characteristics of self-help groups. In fact, participating 
in AA was not an obligatory condition to partake in any of 
our trials, despite the encouragement given by researchers. 
7KLVIDFWFRXOGPHDQWKDWWKHPRVWPRWLYDWHGDQGDIÀOLD-
tive patients decide to participate in AA with the goal of 
improving their coping skills and changing their friendship 
networks.32 Other authors suggest that success in AA is as-
sociated with frequent and continued attendance and not 
with motivation per se.33
$FWLYHPHGLFDWLRQVGLGQRW LQÁXHQFHWUHDWPHQWUHWHQ-
tion in the present study. Other studies have already shown 
that treatment with opioid antagonists,34 topiramate,35 and 
ondansetron, alone or in combination with naltrexone,36,37 
was not associated with increased retention in treatment, 
compared with placebo. Furthermore, even combinations of 
two medications for alcoholism have not shown effects on 
retention in treatment compared with individual pharma-
cotherapies alone.38
Although craving is an important factor to be measured 
and investigated at baseline and during treatment, our 
study was not able to show that it is a strong predictive 
factor of retention, at least when craving intensity was 
computed at baseline only. In reality, craving is not a stable 
state but rather depends on other variables that can be 
PRGLÀHGGXULQJWUHDWPHQWVXFKDVPRRGVWUHVVVXEVWDQFH
using status, environmental cues, etc. Nevertheless, other 
YDULDEOHVVLJQLÀFDQWO\FRUUHODWHGZLWKFUDYLQJVXFKDVDJH
DQGSUHIHUUHGEHYHUDJHZHUHVLJQLÀFDQWO\DVVRFLDWHGZLWK
treatment retention.
Despite the heterogeneity of our clients, many thera-
peutic programs offer only a single type of treatment. With 
WKLV´RQHVL]HÀWVDOOµPRGHOYDULDWLRQVLQUHWHQWLRQKDYH
been commonly attributed to client factors or character-
istics. Although this belief might be true to some extent, 
health services should broaden the scope of services offered 
to meet the heterogeneous needs of clients and identify 
treatment practices and therapies that improve reten-
tion. Information about patients’ characteristics linked to 
noncompliance or dropout should be used to render treat-
ment programs more responsive and attractive, combining 
SKDUPDFRORJLFDJHQWVZLWKPRUHLQWHQVLYHDQGGLYHUVLÀHG
psychosocial interventions. Certain approaches, such as 
compliance enhancement therapy and motivational inter-
views, can be effective options when combining adjunctive 
interventions for randomized clinical trials.39 Strategies to 
improve motivation are of paramount importance in dif-
ferent treatment programs, and they will be taken into 
account in future research by our group.
There were several weaknesses in this present study, 
including the following:
(1) There were no other psychotherapeutic procedures 
associated with the pharmacological treatments, 
which could have increased the retention of the 
patients.
(2) The number of dropouts was high in both trials, 
probably as a result of their designs, which allowed 
patients to follow the standard community-based 
programs of treatment, without norms to increase 
patient retention. Although this approach to trial de-
VLJQZKLFKDOORZVIRUQRUPDOOLIHHYHQWVWRLQÁXHQFH
trial outcomes, probably enhances external validity, 
LWFDQOHDGWRFRQVLGHUDEOHGLIÀFXOWLHVLQLQWHUSUHW-
ing data, such as motives for relapse and premature 
discontinuation of follow-up.
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(3) Additionally, our service is tertiary, and many severe 
FDVHVDUHUHIHUUHGWRLW7KLVIDFWFDQEHYHULÀHGE\
the enormous quantity of ethanol consumed by our 
VXEMHFWV,WLVGLIÀFXOWWRJHQHUDOL]HRXUÀQGLQJVWRD
less severely alcoholic population.
(4) Our research did not include women. Some studies 
KDYHVKRZQWKDWVH[GLIIHUHQFHVH[HUWGLIIHUHQWLQÁX-
ences on retention treatment and craving.40
(5) The dosage of ondansetron tested (16 mg/day) was 
higher than the dosages usually investigated by other 
studies. This fact might have compromised this study’s 
comparability to other studies.
(6) Our trials limited the examination of AA participa-
tion to the frequency and regularity of meeting 
attendance, which failed to capture the breadth of 
involvement in the program.
(7) Although OCDS was measured at three time points 
(at baseline, at the sixth week, and at the twelfth 
week) in each double-blind study, we only evaluated 
the effect on treatment retention of OCDS measured 
at baseline, due to some of the participants having 
discontinued the treatment before the sixth week. 
In this study, our aim was to investigate treatment 
retention in general, without taking into account the 
different times at which dropouts occurred.
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